How are you approaching patient selection and timing of RNA-based NGS, in light of the approval of zenocutuzumab for NRG1 fusion–positive advanced cholangiocarcinoma?

My standard has been to do all DNA, RNA, and IHC through a single vendor. I test all newly diagnosed patients with cholangiocarcinoma. I always do tissue and liquid biopsy NGS. If tissue biopsy is not feasible because of sample quantity/quality, then another biopsy will be the way to go to obtain, e...

The approximate incidence of NRG1 gene fusions in advanced biliary tract cancers is <1%. The largest dataset comes from a Caris Life Sciences analysis of 169,273 tumor specimens using RNA-based sequencing, which found cholangiocarcinoma had the second-highest incidence of NRG1 fusions among all tumo...